Population pharmacokinetic and pharmacodynamic modeling of norvancomycin

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 27, Issue 4, 2008, Pages 275-284

  Zhang, J ^a   Zhang, Y ^a   Shi, Y ^a   Rui, J ^b   Yu, J ^a   Cao, G ^a   Wu, J ^a  

^a FUDAN UNIVERSITY   (China)

^b NANJING GENERAL HOSPITAL OF NANJING MILITARY COMMAND   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DIURETIC AGENT; NORVANCOMYCIN; POLYPEPTIDE ANTIBIOTIC AGENT; VANCOMYCIN;

ADULT; AGAR DILUTION; AGED; ANALYTICAL ERROR; AREA UNDER THE CURVE; ARTICLE; BACTERIUM ISOLATION; COMBINATION CHEMOTHERAPY; COMPARTMENT MODEL; COMPUTER PROGRAM; CONTROLLED STUDY; CREATININE CLEARANCE; DOSE KIDNEY FUNCTION RELATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; ENTEROCOCCAL INFECTION; FEMALE; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; PRIORITY JOURNAL; STAPHYLOCOCCUS INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BACTERIAL INFECTIONS; COMPUTER SIMULATION; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MODELS, BIOLOGICAL; VANCOMYCIN;

EID: 43449091311     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-007-0435-9     Document Type: Article

References (19)

1. Morgan M, Evans-Williams D, Salmon R, Hosein I, Looker DN, Howard A (2000) The population impact of MRSA in a country: the national survey of MRSA in Wales, 1997. J Hosp Infect 44(3):227-239
2. Zhang YY (2001) Development of antibiotics in the treatment of gram-positive cocci infections. Chin J Infect Chemother 1(1):50-53
3. Shanghai Surveillance of Bacterial Resistance Working Group (2002) Surveillance of bacterial resistance in Shanghai. Chin J Infect Chemother 2(1):1-9
4. Wang F (2006) CHINET 2005 surveillance of bacterial resistance in China. Chin J Infect Chemother 6(5):289-295
5. Wang F (2004) Vancomycin and norvancomycin. In: Wang F (ed) Practical anti-infectious therapeutics. People's Medical Publishing House, Beijing, pp 281-283
6. Liu Y, Wu JF, Xiao ZL, Sheng RY, Lu XJ, Chen Y, Zhang YY (2004) The adverse reactions of parenteral norvancomycin in 1031 patients. Chin J Intern Med 43(11):815-819
7. Buelga DS, Gatta MMF, Herrera EV, Dominguez-Gil A, García MJ (2005) Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies. Antimicrob Agents Chemother 49(12):4934-4941
8. Kimura T, Sunakawa K, Matsuura N, Kubo H, Shimada S, Yago K (2004) Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates. Antimicrob Agents Chemother 48(4):1159-1167
9. Sheiner LB, Grasela TH Jr (1991) An introduction to mixed effect modeling: concepts, definitions, and justification. J Pharmacokinet Biopharm 19(Suppl):11S-24S
10. Yasuhara M, Iga T, Zenda H, Okumura K, Oguma T, Yano Y, Hori R (1998) Population pharmacokinetics of vancomycin in Japanese adult patients. Ther Drug Monit 20(2):139-148
11. Zhang Z, Zhai SD (2004) The development of nonlinear mixed effects model in study of pharmacokinetics and pharmacodynamics. Foreign Medical Sciences Section on Pharmacy 31(4):236-240
12. Zhang J, Hu JY, Yu JC, Cao GY, Shi YG, Zhang YY (2003) Clinical pharmacokinetics and therapeutic drug monitoring of norvancomycin. Chin J Infect Chemother 3(4):202-205
13. Craig WA (1998) Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26(1):1-10, quiz 11-12
14. Frimodt-Møller N (2002) How predictive is PK/PD for antibacterial agents. Int J Antimicrob Agents 19:333-339
15. Li C, Kuti JL, Nightingale CH, Mansfield DL, Dana A, Nicolau DP (2005) Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. J Antimicrob Chemother 56(2):388-395
16. Van Wart S, Phillips L, Ludwig EA, Russo R, Gajjar DA, Bello A, Ambrose PG, Costanzo C, Grasela TH, Echols R, Grasela DM (2004) Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 48(12):4766-4777
17. Zhanel GG (2001) Influence of pharmacokinetic and pharmacodynamic principles on antibiotic selection. Curr Infect Dis Rep 3:29-34
18. Zhong SL, Huang M, Zhao XL (2003) Pharmacokinetic/pharmacodynamic parameters: rational for antimicrobial agents dose regimen. Chin J Infect Chemother 3(3):177-180
19. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ (2004) Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 43(13):925-942